Booster shot: Mounjaro may emerge as a sweet pill for Eli Lilly in India

Analysts say the diabetes and obesity drug can be a Rs 500 crore opportunity for the firm

The launch of Eli Lilly’s diabetes and obesity management drug Mounjaro could be a significant opportunity for the company even if a few thousand patients are put on this therapy, feel analysts.

 

Doctors warn that the drug is not for all diabetics and needs to be used with caution.

 

Eli Lilly launched the drug in a single dose vial following the marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO). It has been priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for a 5 mg vial.

 

Dr Hrishikesh Salgaonkar, consultant, bariatric and laparoscopic surgery, Fortis Hospital Mulund,